Navigation Links
Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
Date:11/13/2008

EAST BRUNSWICK, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Christopher Clement, President and Chief Executive Officer of Savient Pharmaceuticals will present a corporate update at the upcoming Lazard Capital Markets 5th Annual Healthcare Conference.

The presentation is scheduled to begin on Tuesday, November 18, 2008 at 9:25 a.m. ET. The Conference will be held at the St. Regis Hotel in New York City November 18-19, 2008.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007 and the BLA was filed with the FDA in October 2008. Savient has exclusively licensed worldwide rights to the technology related to pegloticase, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.

SVNT-G

Contact:

Mary Coleman

Director, Investor Relations

Savient Pharmaceuticals, Inc.

information@savient.com

(732) 418-9300


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
2. Savient Submits Biologics License Application (BLA) for pegloticase
3. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
4. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
5. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
6. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
7. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... report "Biomarkers - Technologies, Markets and Companies" to their ... , , ... biomarkers and their discovery using various -omics technologies such as proteomics ... biomarkers and new tests are also based on biomarker. ...
(Date:12/5/2016)... 5, 2016 According to ... by Products (Consumable, Instruments, Automated Cell Expansion System), ... Stem Cell Research, Cancer, and Cell-Based Research), End-users ... - Global Revenue, Trends, Growth, Share, Size and ... the global cell expansion market is expected to ...
(Date:12/5/2016)... MDx announced today that it brought its NxGen Informed Prenatal Test in-house. ... improve customer service through shortened turnaround times and at the same time ... NxGen MDx. ... A decrease in turnaround times by 25% combined with ... the Grand Rapid headquarters. The NxGen Informed Prenatal Test uses ...
(Date:12/5/2016)... The U.S. Biotechnology industry is ... of revenue and some $890 billion of total market ... biopharmaceuticals, and this figure is expected to exceed $220 ... these four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
Breaking Biology News(10 mins):